补肾解毒方联合程序性死亡受体配体-1抗体对HBV转基因小鼠T细胞免疫应答影响的研究  

Effect of invigorating kidney and detoxicating decoction combined with PD-L1 antibody on T cell immune response in HBV transgenic mice

作　　者：蔡本强[1] 贺劲松[1] 邢宇锋[1] 马晓军[2] 

机构地区：[1]广州中医药大学深圳附属医院肝病科,广东深圳518033 [2]广东省人民医院广东省医学科学院感染科

出　　处：《中西医结合肝病杂志》2013年第3期151-153,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：2010年广东省科技计划资助项目(No.粤科函社字[2010]1096号);2011年深圳市科技计划项目(No.201102196)

摘　　要：目的:观察补肾解毒方联合程序性死亡受体配体-1(PD-L1)抗体免疫,对HBV转基因小鼠特异性细胞毒性T细胞(CTL)细胞免疫应答的影响。方法:HBV转基因小鼠,使用补肾解毒方灌胃,PD-L1腹腔注射,共两周。检测小鼠脾脏淋巴细胞IFN-γ分泌水平、脾脏CD8+T细胞程序性死亡受体-1(PD-1)表达情况及脾脏HBsAg特异性T淋巴细胞体外杀伤活性。结果:免疫两周后,小鼠脾脏淋巴细胞IFN-γ分泌水平与脾脏HBsAg特异性T淋巴细胞体外杀伤活性,联合组明显高于PD-L1抗体组、补肾解毒方组及磷酸盐缓冲液(PBS)组,统计学分析差异均有显著性意义(P<0.01或0.05)。脾脏CD8+T细胞PD-1表达水平,联合组较PD-L1抗体组、补肾解毒方组及PBS组明显降低,差异均有显著性意义(P<0.01或0.05)。结论:补肾解毒方联合PD-L1抗体免疫,可显著提高HBV转基因小鼠体内HBV抗原特异性CTL活性,提高脾脏淋巴细胞分泌IFN-γ水平,能降低脾脏CD8+T细胞表面PD-1分子的表达。这种联合方法有利于恢复慢性HBV感染时T细胞的免疫功能,增强其免疫应答水平。Objective： To observe the effect of a Chinese herbal formula（invigorating the kidney and detoxicating decoction,IKDD） combined with programmed death ligand-1（PD-L1） on the specific cytotoxic T-lymphocyte（CTL） in hepatitis B virus（HBV） transgenic mice.Methods： HBV transgenic mice were intragastric administrated with medication IKDD,combined with intraperitoneal injection of PD-L1 for 2 weeks.Then detected IFN-γ levels in splenic lymphocytes,the expression of PD-1 in splenic CD8＋ T cell,and cytotoxic activity of HBsAg specific T lymphocytes in spleen.Results： After dealt with medication IKDD and PD-L1 for 2 weeks,Test results indicated that IFN-γ levels and cytotoxic activity of HBsAg specific T lymphocytes were both higher than that in either PD-L1 antibody group or IKDD group alone and PBS group（P ＆lt; 0.01 or 0.05）.In the mean time,compared with either PD-L1 antibody group or IKDD group alone,combining medication IKDD and PD-L1 antibody obviously decreased the expression of PD-1 in splenic CD8＋ T cell,there was a statistically significant difference（P ＆lt; 0.01 or 0.05）.Conclusion： Combining medication IKDD and PD-L1 antibody administration in HBV transgenic mice could markedly increase IFN-γ levels and cytotoxic activity of HBV antigen specific CTL,while decrease the expression of PD-1 molecule in the surface of splenic CD8＋ T cell.The combination is beneficial to recover the immunologic function of T cell and enhance the immune response when chronically infected with hepatitis B virus.

关 键 词：程序性死亡受体配体-1 补肾解毒方 药效学 程序性死亡受体-1 转基因小鼠 细胞毒性T细胞 

分 类 号：R392.1[医药卫生—免疫学]